



## Expert Consensus Recommends Sixth Generation Motiva® Silicone Breast Implants

June 21, 2019

An [international consensus](#) of leading breast implant experts recently published in the Aesthetic Surgery Journal helps plastic surgeons better understand current surgical practices and establishes guidelines for surgeons transitioning to bioengineered smooth devices, such as the sixth-generation Motiva® Implants.

“After little innovation in the breast implant industry over the course of decades, Establishment Labs used a patient-centric approach to develop the Motiva® Implants silicone breast implant. The implants’ cell-friendly smooth surface minimizes capsule formation and reduces complications, problems that previous and current implant manufacturers have failed to adequately address,” said Niamh Corduff, M.D., member of Establishment Labs’ Medical Advisory Board, past-President of the Australasian Society of Aesthetic Plastic Surgeons and who has a unique perspective as a surgeon, woman and patient.

The consensus recommendations came out of a survey compiled by a group of plastic surgeon experts in aesthetic and reconstructive breast surgery from across the globe, as well as one biotechnology scientist. Among the topics discussed were surgical techniques, complication rates and implant selection.

The experts agreed on three core principles: The dissected pocket needs to be close fitting and steps must be taken to prevent expansion of the pocket; implant selection must be individualized; and, surgical planning and technique must be carefully considered. Moreover, with respect to overall clinical experience, experts cited switching to Motiva® Implants due to technology (92.3%), softness (76.9%) and safety (61.5%).

When questioned about problems they had encountered, 84.6% of the experts agreed that they experienced fewer overall complications and 76.9% confirmed reduced capsular contracture rates with the Motiva® Implants. Overall, 84.6% of the experts favored selecting Motiva Ergonomix® implants over Round implants to achieve a more natural look. In addition, 92.3% of the experts noted that in their opinion, Motiva® Implants could reduce the risk of anaplastic large-cell lymphoma due to their innovative low-inflammatory surface technology.

By helping plastic surgeons with patient selection, preoperative planning and surgical technique, the study authors hope to optimize surgical outcomes, resulting in lower overall complication rates, more natural-looking breasts and highly satisfied patients.